X

Trial Profile

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Atezolizumab
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms FLUORO

Most Recent Events

04 Jun 2024 Results of atezolizumab and obinutuzumab in First-line treatment of follicular lymphoma were presented at the 60th Annual Meeting of the American Society of Clinical Oncology
26 Nov 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
09 Aug 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com